TREATMENT FOR RETINAL DISORDERS

TREATMENT FOR RETINAL DISORDERS

Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders. Wherein the pharmaceutical composition comprises a therapeutically effectiv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: ZORZÓPULOS, Jorge
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZORZÓPULOS, Jorge
description Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders. Wherein the pharmaceutical composition comprises a therapeutically effective amount of a phosphorothioate oligonucleotide comprising a nucleic acid sequence of at least a 70% sequence identity to SEQ ID NO: 1. Les compositions pour le traitement de troubles rétiniens comprennent un oligonucléotide de phosphorothioate en une quantité thérapeutiquement efficace. L'oligonucléotide de phosphorothioate est administré dans le traitement de troubles rétiniens.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023183556A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023183556A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023183556A33</originalsourceid><addsrcrecordid>eNrjZJAPCXJ1DPF19QtRcPMPUghyDfH0c_RRcPEM9g9ycQ0K5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGxoYWxqamZo7GxsSpAgBqWSK5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TREATMENT FOR RETINAL DISORDERS</title><source>esp@cenet</source><creator>ZORZÓPULOS, Jorge</creator><creatorcontrib>ZORZÓPULOS, Jorge</creatorcontrib><description>Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders. Wherein the pharmaceutical composition comprises a therapeutically effective amount of a phosphorothioate oligonucleotide comprising a nucleic acid sequence of at least a 70% sequence identity to SEQ ID NO: 1. Les compositions pour le traitement de troubles rétiniens comprennent un oligonucléotide de phosphorothioate en une quantité thérapeutiquement efficace. L'oligonucléotide de phosphorothioate est administré dans le traitement de troubles rétiniens.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231123&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023183556A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231123&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023183556A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZORZÓPULOS, Jorge</creatorcontrib><title>TREATMENT FOR RETINAL DISORDERS</title><description>Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders. Wherein the pharmaceutical composition comprises a therapeutically effective amount of a phosphorothioate oligonucleotide comprising a nucleic acid sequence of at least a 70% sequence identity to SEQ ID NO: 1. Les compositions pour le traitement de troubles rétiniens comprennent un oligonucléotide de phosphorothioate en une quantité thérapeutiquement efficace. L'oligonucléotide de phosphorothioate est administré dans le traitement de troubles rétiniens.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJAPCXJ1DPF19QtRcPMPUghyDfH0c_RRcPEM9g9ycQ0K5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGxoYWxqamZo7GxsSpAgBqWSK5</recordid><startdate>20231123</startdate><enddate>20231123</enddate><creator>ZORZÓPULOS, Jorge</creator><scope>EVB</scope></search><sort><creationdate>20231123</creationdate><title>TREATMENT FOR RETINAL DISORDERS</title><author>ZORZÓPULOS, Jorge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023183556A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZORZÓPULOS, Jorge</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZORZÓPULOS, Jorge</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TREATMENT FOR RETINAL DISORDERS</title><date>2023-11-23</date><risdate>2023</risdate><abstract>Compositions in the treatment of retinal disorders include a phosphorothioate oligonucleotide in a therapeutically effective amount. The phosphorothioate oligonucleotide is administered in the treatment of retinal disorders. Wherein the pharmaceutical composition comprises a therapeutically effective amount of a phosphorothioate oligonucleotide comprising a nucleic acid sequence of at least a 70% sequence identity to SEQ ID NO: 1. Les compositions pour le traitement de troubles rétiniens comprennent un oligonucléotide de phosphorothioate en une quantité thérapeutiquement efficace. L'oligonucléotide de phosphorothioate est administré dans le traitement de troubles rétiniens.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2023183556A3
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title TREATMENT FOR RETINAL DISORDERS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A23%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZORZ%C3%93PULOS,%20Jorge&rft.date=2023-11-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023183556A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true